4-%D8%A3%D9%85%D9%8A%D9%86%D9%88_%D8%A7%D9%84%D8%A8%D9%8A%D8%B1%D9%8A%D8%AF%D9%8A%D9%86%DB%B4-%D8%A2%D9%85%DB%8C%D9%86%D9%88%D9%BE%DB%8C%D8%B1%DB%8C%D8%AF%DB%8C%D9%86Category:4-aminopyridineFampridin4-Aminopyridine%DB%B4-%D8%A2%D9%85%DB%8C%D9%86%D9%88%D9%BE%DB%8C%D8%B1%DB%8C%D8%AF%DB%8C%D9%864-Aminopyridine%D7%A4%D7%9E%D7%A4%D7%A8%D7%99%D7%93%D7%99%D7%9F4-Aminopiridin4-Amminopiridina4-Aminopiridin4-Aminopiridin4-%E0%AE%85%E0%AE%AE%E0%AE%BF%E0%AE%A9%E0%AF%8B%E0%AE%AA%E0%AE%BF%E0%AE%B0%E0%AE%BF%E0%AE%9F%E0%AE%BF%E0%AE%A9%E0%AF%8D4-Aminopyridine4-%E6%B0%A8%E5%9F%BA%E5%90%A1%E5%95%B6Q3725394-%E6%B0%A8%E5%9F%BA%E5%90%A1%E5%95%B6
about
Transient receptor potential cation channel, subfamily V, member 2Potassium voltage-gated channel subfamily A member 5Potassium voltage-gated channel subfamily A member 10Potassium voltage-gated channel subfamily B member 2Potassium voltage-gated channel subfamily D member 1Potassium inwardly rectifying channel subfamily J member 13Potassium voltage gated channel, Shaw-related subfamily, member 1Potassium voltage-gated channel, shaker-related subfamily, member 7Potassium voltage-gated channel, Shal-related family, member 1Potassium voltage-gated channel, Shal-related family, member 3Potassium voltage-gated channel, Shal-related family, member 2
P129
Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic SyndromeSafety and Tolerability of Dalfampridine in Subjects With Cerebral PalsyA New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic ProstatectomyCharacterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple SclerosisFampridine Pregnancy Exposure RegistryA Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's DiseaseDalfampridine for Imbalance in Multiple SclerosisAmpyra for Optic Neuritis in MSPharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal ImpairmentStudy of Fampridine-ER Tablets in Patients With Multiple SclerosisOpen Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.High Doses of 4-aminopyridine in Clinically Complete Chronic Spinal Cord Injury Patients.4-aminopyridine Treatment for Nerve Injury
P4844
Impaired voltage gated potassium channel responses in a fetal lamb model of persistent pulmonary hypertension of the newbornNIOSH Manual of Sampling Data Sheets. Supplement to the 1977 EditionDownregulated Kv4.3 expression in the RVLM as a potential mechanism for sympathoexcitation in rats with chronic heart failureAtypical presentation of 4-aminopyridine overdose.An unusual case of 4-aminopyridine toxicity.Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosisTreatment of walking impairment in multiple sclerosis with dalfampridine.Comparative hemodynamic effects of levosimendan alone and in conjunction with 4-aminopyridine or calcium chloride in a rodent model of severe verapamil poisoning.Dalfampridine in multiple sclerosis.Dalfampridine: a new agent for symptomatic management of multiple sclerosis.The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.Clinical overview of the seizure risk of dalfampridine.Sustained-release fampridine and the role of ion channel dysfunction in multiple sclerosis.Voltage-gated K+ channels are associated with cell proliferation and cell cycle of ovarian cancer cell.Potassium channel inhibitors attenuate neuromodulatory effects of atrial natriuretic factor in the rabbit isolated vas deferens.Effects of 4-Aminopyridine on Cloned hERG Channels Expressed in Mammalian Cells.The Na+/K+ATPase mediates the alpha 1-adrenoceptor stimulated increase in 86Rb(+)-uptake in isolated ventricular cardiomyocytes from adult rat heart.Regulation of myometrial phospholipase C system and uterine contraction by beta-adrenergic receptors in midpregnant rat.Functional and molecular identification of pH-sensitive K+ channels in murine urinary bladder smooth muscle.Effects of statins on vascular function of endothelin-1.[4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis].Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment.Apamin reduces neuromuscular transmission by activating inhibitory muscarinic M(2) receptors on motor nerve terminals.Fampridine improves severe dysarthria in secondary-progressive multiple sclerosis.Opisthotonic posturing with neuromuscular irritability attributable to 4-aminopyridine ingestion by a healthy pediatric patient.Blockage of voltage-gated K+ channels inhibits adhesion and proliferation of hepatocarcinoma cells.Effects of 4-aminopyridine on stretched mammalian spinal cord: the role of potassium channels in axonal conduction.Differences in the mechanisms for relaxation of aorta induced by 17beta-estradiol or progesterone between normotensive and hypertensive rats.Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury.4-Aminopyridine activates calcium influx through modulation of the pore-forming purinergic receptor in human peripheral blood mononuclear cells.Influence of enteric-coated lactose on the release profile of 4-aminopyridine from HPMC matrix tablets.Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis.Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers.4-Aminopyridine derivatives enhance impulse conduction in guinea-pig spinal cord following traumatic injury.In ovo neuromuscular stimulation alters the skeletal muscle phenotype of the chick.Epileptiform activity induced by pharmacologic reduction of M-current in the developing hippocampus in vitro.Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error.4-aminopyridine, a Kv channel antagonist, prevents apoptosis of rat cerebellar granule neurons.H2O2 activates redox- and 4-aminopyridine-sensitive Kv channels in coronary vascular smooth muscle[Severe poisoning by 4-aminopyridine in a body builder]
P921
Q15323688-09FB3197-0207-48B8-A196-E96D101FBCFAQ21096394-571D2E0C-DD3F-44EE-840F-D742E6FA1A0FQ21107843-A708ABCA-6415-4C73-9E70-22450E3A8DAAQ21107885-5B7F886E-C944-407D-93FE-FA4EE446B61AQ21107891-82B05E77-952A-4925-A717-A6C823AEF192Q21113504-D8A0B37C-1AD7-46D6-A771-00BCEA7AAB3AQ21496563-AC7B5A55-4718-4FB3-BE61-D19173025A24Q21496564-BC6CEA3B-F16F-44A1-AF76-0C1FB66AFD9DQ21984557-C2333428-6C28-48D7-ABE0-BC22113788CCQ21984577-94C3EE90-6D0C-4200-864A-5984F500E4B5Q21984578-F93B0859-F9C2-4364-A0F2-8761F7FC970D
P129
Q61955943-162DDF9C-F13C-43FC-B6A6-A6A488AFA544Q61955998-C7907D14-EFB4-4395-8F98-11990425F927Q61974967-A8D5D891-D106-4171-ADD2-7CA7E00C4BD7Q62062537-BEE279D5-A30F-4A45-AF4F-FC75ED798686Q63315697-D1F284FF-8352-4F55-ACE3-5B679194A9B7Q63316533-E4BD32AA-ED25-41A5-9C4D-FBA9B24C2B97Q63320648-443119F3-CE82-4703-A7FF-0D29EE9FB0B3Q63321841-15B7389F-41B5-4B22-B47C-070B4BA36F16Q63335142-0E227D92-AD1F-4C4A-9A39-7EFA41F82105Q63338179-74C4EE8D-B2B4-4F4B-9C62-9B3B339FD148Q63338535-98949922-A806-4E46-8252-0923095B2DCAQ63340769-28E88359-FD5A-4C8E-93CF-7A42034CC351Q63579214-18BF9F09-9B86-40CD-ADF6-70D2737E7F3DQ63596874-1FF2A2C3-8B9A-4101-AFDA-26DDF4006A6A
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
4-Aminopiridin
@sh
4-Aminopiridin
@sr
4-Aminopyridin
@de
4-Aminopyridine
@vi
4-aminopiridin
@hu
4-aminopiridina
@it
4-aminopyridine
@fr
4-أمينو البيريدين
@ar
4-அமினோபிரிடின்
@ta
4-氨基吡啶
@wuu
type
label
4-Aminopiridin
@sh
4-Aminopiridin
@sr
4-Aminopyridin
@de
4-Aminopyridine
@vi
4-aminopiridin
@hu
4-aminopiridina
@it
4-aminopyridine
@fr
4-أمينو البيريدين
@ar
4-அமினோபிரிடின்
@ta
4-氨基吡啶
@wuu
altLabel
4-AP
@en
4-AP
@fr
4-AP
@nn
4-Aminopyridine
@en
4-Pyridinamine
@en
4-Pyridylamin
@de
4-Pyridylamine
@en
4-aminopyridin
@nn
4-aminopyridine
@en
4-pyridinamine
@fr
prefLabel
4-Aminopiridin
@sh
4-Aminopiridin
@sr
4-Aminopyridin
@de
4-Aminopyridine
@vi
4-aminopiridin
@hu
4-aminopiridina
@it
4-aminopyridine
@fr
4-أمينو البيريدين
@ar
4-அமினோபிரிடின்
@ta
4-氨基吡啶
@wuu